The Legal Examiner Mark The Legal Examiner Mark The Legal Examiner Mark search twitter facebook feed linkedin instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

Takeda Pharmaceutical Co., maker of the diabetes drug Actos, has launched a new marketing campaign designed to take advantage of Avandia’s recent woes. In the new print edition advertisements, the marketing execs state that Actos lowers blood sugar without increasing the risk of heart attack. The ad copy cites “studies” to bolster its argument. However, as is often the case, no scientific sources are cited. This raises the ethical dilemna with which the FDA has to wrestle. When do pharmaceutical companies’ efforts to market their products cross the ethical line and become a threat to consumer safety? There should be a balance between good science and the company’s desire to make a profit.

For more information on this subject, please refer to the section on Drugs, Medical Devices, and Implants.

Comments are closed.

Of Interest